CNR1 and cancer: Therefore, it is possible that SERMs exhibiting a dual mechanism of action to both antagonize ER function and act as CBR inverse agonists might exhibit superior therapy and lead to development of a novel class of specialized SERMs for use in personalized cancer therapy.